1. Home
  2. AKTX vs RAYA Comparison

AKTX vs RAYA Comparison

Compare AKTX & RAYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKTX
  • RAYA
  • Stock Information
  • Founded
  • AKTX N/A
  • RAYA 2019
  • Country
  • AKTX United States
  • RAYA China
  • Employees
  • AKTX N/A
  • RAYA N/A
  • Industry
  • AKTX Biotechnology: Pharmaceutical Preparations
  • RAYA Metal Fabrications
  • Sector
  • AKTX Health Care
  • RAYA Consumer Discretionary
  • Exchange
  • AKTX Nasdaq
  • RAYA Nasdaq
  • Market Cap
  • AKTX 37.2M
  • RAYA 103.6M
  • IPO Year
  • AKTX N/A
  • RAYA 2022
  • Fundamental
  • Price
  • AKTX $1.14
  • RAYA $2.53
  • Analyst Decision
  • AKTX
  • RAYA
  • Analyst Count
  • AKTX 0
  • RAYA 0
  • Target Price
  • AKTX N/A
  • RAYA N/A
  • AVG Volume (30 Days)
  • AKTX 26.9K
  • RAYA 538.6K
  • Earning Date
  • AKTX 08-18-2025
  • RAYA 01-01-0001
  • Dividend Yield
  • AKTX N/A
  • RAYA N/A
  • EPS Growth
  • AKTX N/A
  • RAYA N/A
  • EPS
  • AKTX N/A
  • RAYA N/A
  • Revenue
  • AKTX N/A
  • RAYA $30,300,360.00
  • Revenue This Year
  • AKTX N/A
  • RAYA $20.95
  • Revenue Next Year
  • AKTX N/A
  • RAYA N/A
  • P/E Ratio
  • AKTX N/A
  • RAYA N/A
  • Revenue Growth
  • AKTX N/A
  • RAYA 49.10
  • 52 Week Low
  • AKTX $0.85
  • RAYA $0.56
  • 52 Week High
  • AKTX $4.40
  • RAYA $3.14
  • Technical
  • Relative Strength Index (RSI)
  • AKTX 43.82
  • RAYA 58.42
  • Support Level
  • AKTX $1.10
  • RAYA $2.31
  • Resistance Level
  • AKTX $1.18
  • RAYA $2.99
  • Average True Range (ATR)
  • AKTX 0.05
  • RAYA 0.41
  • MACD
  • AKTX 0.00
  • RAYA 0.01
  • Stochastic Oscillator
  • AKTX 39.52
  • RAYA 58.50

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

About RAYA Erayak Power Solution Group Inc.

Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.

Share on Social Networks: